Tag Archives: Johnson & Johnson

Missouri Court Awards $70 Million in Johnson & Johnson Talcum Powder Lawsuit

Posted in Defective Drugs

Another talcum powder lawsuit has seen favorable results in Missouri. Unlike in New Jersey, where Multicounty Litigation (MCL) Judge Nelson C. Johnson rejected the science linking talc to ovarian cancer claims, a Missouri court again ruled in favor of the plaintiff—this time to the tune of $70 million. The plaintiff, Deborah Giannecchini of Modesto, California… Continue Reading

NJ’s Evolving Expert Opinion Standard and its Effect on Multicounty Mass Tort Litigation

Posted in Defective Drugs

On September 2, 2016, New Jersey Superior Court Judge Nelson Johnson issued an Order and Opinion barring Plaintiffs’ experts in the ongoing litigation involving claims against Johnson & Johnson, alleging ovarian cancer caused by the drug maker’s talc products. For those that follow Mass Tort litigation in New Jersey, that decision was significant, but not… Continue Reading

Petition Denied for DePuy MDL Appeal

Posted in DePuy Pinnacle

The 5th District court in Texas recently denied a petition by defendants, Johnson & Johnson and DePuy Orthopedics, Inc., to grant an expedited appeal and to halt the next round of bellwether trials in the Pinnacle multidistrict litigation (MDL), which are currently scheduled to begin in early September 2016. The defendants filed the petition after… Continue Reading

Xarelto Cases Consolidated in New Orleans, Louisiana

Posted in Defective Drugs, Xarelto

The United States Judicial Panel on Multi-District Litigation (MDL) recently convened to determine whether the cases, known as IN RE: XARELTO (RIVAROXABAN) PRODUCTS LIABILITY LITIGATION, should be given MDL treatment. Granting MDL treatment consolidates all federal lawsuits filed across the United States into one centralized district. This consolidation streamlines the pretrial discovery process, allowing the… Continue Reading

Xarelto Injuries Continue To Be Reported

Posted in Defective Drugs, Xarelto

Xarelto (Rivaroxaban) is a blood thinner that was approved by the U.S. Food & Drug Administration (FDA) in July 2011, to prevent strokes in patients who received hip and knee replacements. In November 2011, the approval was expanded to any patients with atrial fibrillation (irregular heartbeat). Since its approval, there have been numerous reports of… Continue Reading

Xarelto Allegedly Not Safer Than Warfarin

Posted in Defective Drugs, Xarelto

Xarelto is marketed as an anticoagulant prescribed to reduce the risk of stroke, deep-vein thrombosis and pulmonary embolism. It is manufactured in the United States by Bayer and Johnson & Johnson’s New Jersey-based division, Janssen Pharmaceuticals. Lawsuits have been filed nationwide based on claims that Xarelto is responsible for injuries in some individuals. Lawsuits allege… Continue Reading